AstraZeneca PLC
AI might be reading your Slack messages: 'A lot of this becomes thought crime'
Insta_photos | Istock | Getty Images Cue the George Orwell reference. Depending on where you work, there’s a significant chance that artificial intelligence is analyzing your messages on Slack, Microsoft Teams, Zoom and other popular apps. Huge U.S. employers such as Walmart, Delta Air Lines, T-Mobile, Chevron and Starbucks, as well as European brands including […]
Read More
Morgan Stanley likes biopharma as a defensive participate in — giving just one stock 119% upside
The biopharmaceutical sector is expected to provide a safe haven from macroeconomic and earnings problems in advance of ultimate quarterly effects from companies, in accordance to Morgan Stanley. The Wall Street financial institution mentioned European biopharma inventory charges really should be supported in the in close proximity to expression, owing to “undemanding valuations and a […]
Read More
The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which could […]
Read More
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. […]
Read More
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because […]
Read More
Biden administration's Medicare drug price negotiations will face major tests in 2024
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the […]
Read More
Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the maker […]
Read More
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More
Is Novo Nordisk a get? Wall Avenue banking companies weigh in — and one offers it 36% draw back
For a lot of traders, the pounds loss drug boom has boosted Danish pharmaceutical big Novo Nordisk ‘s appeal this calendar year — but just one financial investment bank has reservations. “Above the coming yr, we envisage sentiment to change, most likely originally as a final result of the launch of competitor Eli Lilly ‘s […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More